Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 May 20];7(6):s239. Available from: https://skin.dermsquared.com/skin/article/view/2361